Goldstein Stuart L, Mattoo Tej K, Morgenstern Bruce, Martz Karen, Stablein Donald, Talley Lynya
Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA.
Pediatr Transplant. 2007 Mar;11(2):201-4. doi: 10.1111/j.1399-3046.2006.00657.x.
We conducted a retrospective review of the North American Renal Transplant Cooperative Study (NAPRTCS) Registry transplant and dialysis arms to assess anemia and growth patterns in children who returned to dialysis after a failed renal transplant from January 1, 1992 to February 3, 2004. Of the 1807 potential study subjects, 1451 had transplant removal data (TxIn vs. TxOut) available for analysis. Four hundred and twenty-one of 1451 patients (29%) had a transplant nephrectomy at the time of entry into the NAPRTCS Registry Dialysis arm. Anemia rates steadily decreased from 72.2% at 30 days after dialysis initiation to 59.5% at 12 months after dialysis initiation. Factors associated with anemia at 30 days after dialysis initiation included hemodialysis, lack of Epo use, and patients who comprised earlier study era cohorts. At one yr after return to dialysis, earlier study cohort era was the only factor associated with anemia status. Patients did not demonstrate significant improvement in height SDS over the course of the study (-2.17 at day 30 to -2.32 at 24 months). The high anemia, poor growth, and low recombinant human growth hormone utilization rates in a group of patients followed longitudinally as they transition from renal transplant to dialysis should cause the pediatric nephrology community to reassess the processes in place to provide optimal care to pediatric end-stage renal disease patients.
我们对北美肾移植协作研究(NAPRTCS)登记处的移植和透析队列进行了回顾性分析,以评估1992年1月1日至2004年2月3日肾移植失败后重新开始透析的儿童的贫血和生长模式。在1807名潜在研究对象中,1451名有移植移除数据(移植入组与移植出组)可供分析。1451名患者中有421名(29%)在进入NAPRTCS登记处透析队列时进行了移植肾切除术。贫血率从透析开始后30天的72.2%稳步下降至透析开始后12个月的59.5%。透析开始后30天与贫血相关的因素包括血液透析、未使用促红细胞生成素以及属于早期研究队列的患者。重新开始透析1年后,早期研究队列时期是与贫血状态相关的唯一因素。在研究过程中,患者的身高标准差评分没有显著改善(第30天为-2.17,24个月时为-2.32)。一组从肾移植过渡到透析的患者长期随访中出现的高贫血率、生长不良以及重组人生长激素利用率低的情况,应促使儿科肾脏病学界重新评估为儿科终末期肾病患者提供最佳护理的现有流程。